Labshake search
Citations for Phoenix Pharmaceuticals :
1 - 7 of 7 citations for ARALAR1 Blocking Peptide since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Molecular Biology 2023Quote: Ghrelin peptides (Catalog #031-30)(Phoenix Pharmaceuticals, Inc.). Mice were injected with reconstituted ghrelin (0.1 mg/kg ...
-
bioRxiv - Physiology 2022Quote: Chemically synthetic Ins peptides were prepared by Phoenix Pharmaceuticals Inc ...
-
bioRxiv - Neuroscience 2021Quote: CRF peptide was purchased from Phoenix Pharmaceuticals (Burlingame, CA, USA). R-7050 ...
-
bioRxiv - Neuroscience 2024Quote: Lyophilized CART peptide (55-102) (003-62, Phoenix Pharmaceuticals, CA, USA) was reconstituted in 0.2 M PBS to obtain a stock concentration of 1 ug/ul ...
-
bioRxiv - Neuroscience 2024Quote: ... The following peptides were used: PACAP1-38 (30-3000nM; Phoenix Pharmaceuticals; #052-05), VIP (3000nM ...
-
bioRxiv - Developmental Biology 2024Quote: ... followed by blocking solution and primary antibody incubation with anti-urocortin3 (rabbit, Phoenix Pharmaceuticals H-019-29, 1:300) and anti-glucagon (mouse ...
-
bioRxiv - Pharmacology and Toxicology 2019Quote: ... Plasma was separated and stored at −80°C prior to determination of exendin-4 / lixisenatide concentration using an ELISA which equally cross reacts with both peptides (Exendin-4 fluorescent EIA Kit, Phoenix Pharmaceuticals).